Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - Single center experience

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 7, 2009, Pages 819-823

  Armbrust, Thomas ^a   Sobotta, Michael ^a   Gunawan, Bastian ^a   Füzesi, Laszlo ^a   Langer, Claus ^b   Cameron, Silke ^b   Ramadori, Giuliano ^b  

^a Department of Gastroenteropathology ^*  (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

c kit mutations; Gastrointestinal stromal tumors; Imatinib; Resistance

Indexed keywords

IMATINIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER METASTASIS; MALE; NAUSEA; PERITONEUM METASTASIS; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, AMINO ACID; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67651012675     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32830b0f76     Document Type: Article

References (34)

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580. (Pubitemid 28067289)
2. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15:1293-1301. (Pubitemid 30763074)
3. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7:705-712. (Pubitemid 30764739)
4. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int 2006; 56:1-9.
5. Hudson NP, Mayhew IG, Pearson GT. Interstitial cells of Cajal and electrical activity of smooth muscle in porcine ileum. Acta Physiol 2006; 187:391-397. (Pubitemid 43876254)
6. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD. Gastrointestinal stromal tumors may originate from a subset of CD34- positive interstitial cells of Cajal. Am J Pathol 2000; 156:1157-1163. (Pubitemid 30659992)
7. Vliagoftis H, Worobec AS, Metcalfe DD. The protooncogene c-kit and c-kit ligand in human disease. J Allerg Clin Immunol 1997; 100:435-440. (Pubitemid 27441296)
8. Rubin BP, Singer S, Tsao C, Dünsing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118-8121.
9. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000; 157:1091-1095. (Pubitemid 30757930)
10. Kinoshita K, Isozaki K, Hirota S, Nishida T, Chen H, Nakahara M, et al. C-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003; 18:147-151. (Pubitemid 36349859)
11. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-145. (Pubitemid 30746073)
12. Heinrich MC, Griffith DJ, Druker BJ,Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-932.
13. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crises of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Eng J Med 2001; 344:1038-1043. (Pubitemid 32267973)
14. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002; 93:79-98. (Pubitemid 34615551)
15. Fabbro D, Parkinson D, Matter A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2002; 2:374-381.
16. Druker BJ, David A. Karnofsky award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21(Suppl 23):239s-245s.
17. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci 1995; 92:2558-2562.
18. Debiec-Rychter M, Dumez H, Judson I,Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40:689-695. (Pubitemid 38326618)
19. Joensuu H, Roberts P, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056. (Pubitemid 32267975)
20. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134 (Pubitemid 39296599)
21. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarkoma Group - Australasian Gastrointestinal Trials Group. J Clin Oncol 2005; 23:5795-5804. (Pubitemid 46300176)
22. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1-12. (Pubitemid 32128184)
23. DeMatteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33:466-477. (Pubitemid 34747865)
24. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. Kit mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 2006; 42:1093-1103. (Pubitemid 44275331)
25. Schindler CG, Armbrust T, Gunawan B, Langer C, Füzesi L, Ramadori G. Gastrointestinal stromal tumor (GIST) - single center experience of prolonged treatment with Imatinib. Z Gastroenterol 2005; 43: 267-273. (Pubitemid 40461422)
26. Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgo J, et al. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 2005; 11:6589-6597. (Pubitemid 41338999)
27. Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, et al. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2004; 40: 1327-1331. (Pubitemid 38737018)
28. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83: 926-932.
29. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465. (Pubitemid 34747864)
30. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349. (Pubitemid 46621810)
31. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumors crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. Eur J Cancer 2005; 41:1751-1757.
32. Bhattacharya S, Chouldry A, Ravi S, Morrissey J, Mathew G. Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report. J Med Case Reports 2008; 2:110. (Pubitemid 351827628)
33. Darkow T, Henk H, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481-496. (Pubitemid 46849189)
34. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 2006; 24 (Suppl 18):6119.